Nupur Kikani, M.D.
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, HOUSTON, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, HOUSTON, TX
Education & Training
Degree-Granting Education
| 2016 | Baylor College of Medicine, Houston, Texas, US, General Medicine, Doctorate of Medicine (MD) |
| 2011 | Rice University, Houston, Texas, US, Economics, Bachelor of Arts |
Postgraduate Training
| 2019-2021 | Clinical Fellowship, Endocrinology, Diabetes and Metabolism Fellow, Baylor College of Medicine, Houston, Texas |
| 2016-2019 | Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2026 | Texas Medical Board License |
| 2024 | American Board of Internal Medicine Endocrinology, Diabetes and Metabolism |
| 2019 | American Board of Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Director, Endocrine IOTOX Programs - Clinical, Endocrine Neoplasia & HD, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Department Patient Safety and Quality Officer, Endocrine Neoplasia & HD, The University of Texas MD Anderson Cancer Center, 2025 - Present
Associate Patient Safety Quality Officer, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - 2025
Wellness Lead and Department Representative on Divisional Wellness Committee, Endocrine Neoplasia & HD, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Intramural Institutional Committee Activities
Member, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, DOIM Education Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Extramural Institutional Committee Activities
Invited Member, IOTOX Clinical Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Executive Board Member, Academy of Resident Educators, Baylor College of Medicine, The University of Texas MD Anderson Cancer Center, 2017 - 2019
Department representative, Internal Medicine Faculty Wellness Committee, The University of Texas MD Anderson Cancer Center
Honors & Awards
| 2026 - Present | Distinguished Paper Award in Quality and Safety 2025, The University of Texas MD Anderson Cancer Center |
| 2019 | Academy of Resident Educators Distinguished Educator |
| 2015 | Effie and Wofford Cain Scholar |
| 2007 - 2016 | Rice - Baylor Medical Scholar |
| 2007 - 2011 | National Merit Scholar |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Systemic Toxicity with Hyperglycemia and Diabetic Ketoacidosis after Enfortumab Vedotin therapy. Invited. Endocrine Research Seminar Series. Houston, Texas, US.
- 2026. Identifying early predictive markers for immune checkpoint inhibitor related hypophysitis. Invited. FY26 IOTOX Research Seminar. Houston, Texas, US.
- 2026. Immune Related Adverse Events in Endocrinology. Invited. FY26 IOTOX Clinical Education Lecture Series. Houston, Texas, US.
- 2026. Immune Optic Neuropathy Unveiled: Distinct Flavors of a Complex Disorder. Panelist. FY26 IOTOX Clinical Education Series. Houston, Texas, US.
- 2026. Neoplasia Therapy and Diabetes. Invited. Diabetes Academic Meeting. Houston, Texas, US.
- 2026. Morbidity & Mortality: Endocrinology. Invited. FY26 IOTOX Clinical Education Lecture Series. Houston, Texas, US.
- 2026. Immunotherapy-Induced Diabetes in the Oncology Population. Invited. FY26 Glycemic Management Committee Diabetes Lecture Series. Houston, Texas, US.
- 2025. Immunotherapy Related Adverse Events in Endocrinology. Invited. FY25 IOTOX Clinical Education Lecture Series. Houston, Texas, US.
- 2025. Immunotherapy-related adverse events in Endocrinology – initial recognition and management. Invited. General Internal Medicine Clinical and Research Conference. Houston, Texas, US.
- 2025. Increasing Access and Quality Care for Immune Checkpoint Inhibitor- Related Thyroid Dysfunction. Invited. Division of Internal Medicine Research Grand Rounds. Houston, Texas, US.
- 2025. Immunotherapy Induced Diabetes Mellitus in the Oncology Population. Invited. Glycemic Management Committe Diabetes Lecture Series. Houston, Texas, US.
- 2025. Improving Access and Outcomes for Immune-Related Thyroid Dysfunction. Invited. FY25 IOTOX Research Seminar Series. Houston, Texas, US.
- 2024. Non-insulin therapy Overview in the Oncology Population. Invited. Glycemic Management Committee Diabetes Lecture Series. Houston, Texas, US.
- 2023. Insulin Pumps and Continuous Glucose Monitoring in the Oncology Patient. Invited. Glycemic Management Committee Diabetes Lecture Series. Houston, Texas, US.
- 2023. Identifying Trends in Glycemic Management in the Acute Cancer Care Center at MD Anderson Cancer Center. Poster. Oncologic Emergency Medicine Conference 2023. Houston, Texas, US.
- 2019. Improving Patient Safety Through Information: Implementation of an Overnight Handoff System. Conference. Improving Patient Safety Through Information: Implementation of an Overnight Handoff System. Houston, TX, US.
- Fadraciclib: A case report on severe hyperglycemia after initiation of this cancer therapy in relation with CDK2 activity. Poster. Cancer Nursing Conference: Transforming Cancer Nursing Care through Quality Improvement, Evidence-Based Practice, and Research. Houston, Texas, US.
- Immunotherapy-related Adverse Events in Endocrinology. Invited. IOTOX Education Session for Genitourinary Research Nurses. Houston, Texas, US.
Regional Presentations
- 2025. Update in Insulin Pumps and Continuous Glucose Monitors. Invited. Texas Endocrine Association Meeting 2025.
National Presentations
- 2026. Adrenal Insufficiency from Immune Checkpoint Inhibitors. Invited. Adrenal Insufficiency United Summit on Adrenal Insufficiency. Astoria, OR, US.
- 2024. Endocrine Immune related adverse events. Invited. 2024 IOTOX Symposium: Treating Immune-Related Adverse Events – Integrating Insights from Clinical, Translational and Basic Science. Houston, Texas, US.
- 2023. Immunotherapy related adverse events in Endocrinology. Invited. 2023 IOTOX Symposium: Treating Immune-Related Adverse Events – Integrating Insights from Clinical, Translational and Basic Science. Houston, Texas, US.
- 2020. A Lipomatous problem: a case of familial hypercholesterolemia. Poster. AACE Innovation in Cardiometabolic Clinical Practice. Virtual, US.
International Presentations
- 2025. Recurrence of Multiple Myeloma Presenting as a Thyroid Plasmacytoma in a Patient with Long-standing Thyroid Nodules. Poster. ENDO 2025. Washington, US.
- 2024. Use of Continuous Glucose Monitoring System Versus Capillary Point of Care Testing in Hospitalized Patients with Diabetes at a Large Cancer Hospital. 17th International Conference on Advanced Technologies & Treatments for Diabetes. Florence, IT.
- 2023. Identifying Trends in Glycemic Management in a Comprehensive Cancer Center. Poster. ENDO 2023. Chicago, US.
- 2021. Serum Branch Chain Amino Acids (BCAAs) Are Elevated Due to Decreased Catabolism in Patients with Ketosis-Prone Diabetes at the Time of Presentation With DKA. Poster. ENDO 2021. Virtual, US.
- 2018. Cry, Cry Again: A Case of Idiopathic Cryoglobulinemia. Poster. American Society of Nephrology Kidney Week. San Diego, US.
- 2018. Addition of Everolimus to Lenvatinib Halts Tumor Progression in Differentiated Thyroid Cancer. Poster. 88th Annual Meeting of the American Thyroid Association. Washington, US.
Selected Publications
Peer-Reviewed Articles
- Williams JK, Brinkman AK, Salami-Henry AY, Kikani NK, Weitzman SP. Treatment-Refractory Hypothyroidism due to Proteinuria During Combined Immune Checkpoint and Tyrosine Kinase Inhibitor Therapy – A Case Report. Clinical Medicine Insights: Endocrinology and Diabetes 19, 2026. e-Pub 2026.
- Williams, JK, Brinkman, AK, Salami-Henry, AY, Kikani, NJ, Weitzman, SP. Treatment-Refractory Hypothyroidism due to Proteinuria During Combined Immune Checkpoint and Tyrosine Kinase Inhibitor Therapy – A Case Report. Clinical Medicine Insights: Endocrinology and Diabetes 19, 2026. e-Pub 2026. PMID: 42473548.
- Brinkman, AK, Salami-Henry, AY, Aaron-Brija, LA, Hannah, FM, Hu, MI, Hwang, LL, Patel, RP, Rollins, JL, Sherman, SI, Williams, JK, Kikani, NJ, Weitzman, SP. Increasing Access and Quality Care for Immune Checkpoint Inhibitor–Related Thyroid Dysfunction. JCO Oncology Practice 19, 2025. e-Pub 2025. PMID: 41418091.
- Moussa, MJ, Wilson, NR, Ghosh, A, Bhattacharjee, M, Curry, JL, Cho, WC, Patel, A, Habra, MA, Thosani, S, Campbell, M, Siefker-Radtke, AO, Alhalabi, O, Kikani, NJ. Systemic Toxicity With Hyperglycemia or Diabetic Ketoacidosis After Enfortumab Vedotin. Annals of Internal Medicine Clinical Cases 4(5), 2025. e-Pub 2025.
- Astudillo MF, Winter WE, Billings LK, Kreienkamp R, Balasubramanyam A, Redondo MJ, Tosur M, RADIANT Study Group. Identification of atypical pediatric diabetes mellitus cases using electronic medical records 12(6), 2024. e-Pub 2024. PMID: 39510599.
- RADIANT Study Group. The Rare and Atypical Diabetes Network (RADIANT) Study: Design and Early Results. Diabetes Care 46(6):1265-1270, 2023. e-Pub 2023. PMID: 37104866.
- Kikani N, Wilson N, Ghosh A, Bhattacharjee M, Curry J, Cho W, Patel A, Habra A, Thoani S, Campbell M, Siefker-Radtke A, Alhalabi O. Systemic Toxicity With Hyperglycemia or Diabetic Ketoacidosis After Enfortumab Vedotin: Single-Center Case Series. Annals of Internal Medicin: Clinical Cases 4(5).
Review Articles
- Iyer, PC, Kikani, NJ, Khan, S, Chaudhari, A, Pagnotti, GM, Best, CJ, Weitzman, SP, Mehta, PB, Lavis, VR, Thosani, S, Gandhi, A, Aguirre, RS, Varghese, J, Guise, TA, Dadu, R. The evolving management of endocrine disorders induced by checkpoint inhibitors: insights from the CIITED group. Expert Review of Endocrinology and Metabolism 21(1):29-41, 2026. e-Pub 2026. PMID: 41307239.
- Kotwal, A, Kennedy, R, Kikani, NJ, Thosani, S, Goldner, WS, Shariff, A. Endocrinopathies Associated With Immune Checkpoint Inhibitor Use. Endocrine Practice 30(6):584-591, 2024. e-Pub 2024. PMID: 38554775.
- Kikani, NJ, Balasubramanyam, A. Remission in Ketosis-Prone Diabetes. Endocrinology and Metabolism Clinics of North America 52(1):165-174, 2023. e-Pub 2023. PMID: 36754492.
Other Articles
- Moura MJ, Chatterjee A, Wali S, Garza DR, Salim H, Rong J, Menon R, Jafri F, Urias A, Rivera, Mortan R, Palaskas NL, Reynolds KL, Rebecca, Leaf K, Kikani N, Thomas A, Zhang HC, Wang LS, Tummala S, Al-Zubidi N, Sheshadri A, Abudayyeh A, Jeff YL, Wang Y Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review. Expert Opinion on Drug Safety, 2026.
Abstracts
- Brinkman AK, Salami-Henry AY, Aaron-Brija LA, Hannah FM, Hu MI, Hwang L-L, Kikani NJ, Patel RP, Rollins JL, Sherman SI, Williams JK, Weitzman SP. Immune Checkpoint Inhibitor Related Thyroid Dysfunction: A Quality Improvement Project to Improve Access to Endocrine Care and Expedite Normalization of Thyroid Hormone Levels. 2024 Annual Meeting of the American Thyroid Association 34(1), 2024. e-Pub 2024.
- Monroy A, Khan S, Kikani N, Brady VJ, Thosani SN. Fadraciclib induced hyperglycemia. American Association of Clinical Endocrinology (AACE), 2024. e-Pub 2024.
- Thosani S, Grami P, Crowder V, Kikani N. Sweet success: Implementation of institution wide glycemic management initiative. International Forum on Quality and Safety in Healthcare, 2024. e-Pub 2024.
- Kikani N, Thosani S. Identifying Trends in Glycemic Management in the Acute Cancer Care Center at MD Anderson Cancer Center. Oncologic Emergency Medicine Conference 66:e51-52, 2024. e-Pub 2024.
- Kikani N, Thosani S. Use of Continuous Glucose Monitoring System versus Capillary Point of care testing for inpatient Glucose monitoring in a cancer hospital. ENDO 2023 (Endocrine Society), 2023. e-Pub 2023.
- Kikani N, Thosani S. Use of Continuous Glucose Monitoring System Versus Capillary Point of Care Testing in Hospitalized Patients with Diabetes at a Large Cancer Hospital. 17th International Conference on Advanced Technologies & Treatments for Diabetes 26(2).
- Brinkman AK, Salami-Henry AY, Aaron-Brija LA, Hannah FM, Hu MI, Hwang L-L, Kikani NJ, Patel RP, Rollins JL, Sherman SI, Williams JK, Weitzman SP. Improving Access and Quality Care for Immune Checkpoint Inhibitor Related Thyroid Dysfunction. The University of Texas MD Anderson Cancer Center DoIM Research Retreat.
- Williams J, Kikani N, Weitzman S. A Unique Patient With Immune Checkpoint Inhibitor-Induced Thyroiditis: What’s the Kidney Have to Do With It?.
- Thosani S, Grami P, Crowder V, Kikani N. Sweet success: Implementation of institution wide glycemic management initiative. Patient Safety Awareness Week.
- Rizk M, Kikani N. Recurrence of Multiple Myeloma Presenting as a Thyroid Plasmacytoma in a Patient with Long-standing Thyroid Nodules. ENDO 2025.
- Kikani N, Montes G, Gaba R, Liao G, Tosur M, Redondo M, Balasubramanyam A. Identifying Atypical Diabetes Using i2b2 Algorithms in Electronic Health Records. American Diabetes Association 82nd Scientific Sessions.
Book Chapters
- Faruqi, J, Tetlay, M, Kikani, NJ. Thyroid Cancer. In: Caring for the Female Cancer Patient – Gynecologic Considerations. Cambridge University Press, 362-382, 2024.
- Kikani N, Balasubramanyam A. Impact of HIV on the Hypothalamic-Pituitary Hormonal Axis. In: Pituitary Disorders throughout the Life Cycle. Springer Nature, 351-361, 2022.
- Kikani N. Endocrine Complications of Immune Checkpoint Inhibitors. In: Oncology Hospital Medicine: A Guide for the Frontline Clinicians. Springer Nature.
- Kikani N. Thyroid Dysfunction in the Hospitalized Patient. In: Oncology Hospital Medicine: A Guide for the Frontline Clinicians. Springer Nature.
- Kikani N, Gaba R. Primer on Graves’ disease – what the ophthalmologist should know and do. In: International Ophthalmology Clinics: Winter, 2021.
Web Publications
- Kikani N. Diabetes 101: Causes, symptoms and treatment.
- Kikani N. What is the glycemic index?.
- Kikani N, Mutchler C. Weight Loss Drugs May Reduce the Risk of Some Cancers.
- Kikani N, Weitzman S. 10 thyroid myths you shouldn’t believe.
Patient Reviews
CV information above last modified September 11, 2026